Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned September 30, 2025
86% OS at 9 Months observed in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP September 30, 2025
FDA Granted Orphan Drug Designation to Utidelone for the Treatment of Pancreatic Cancer September 30, 2025
ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable pancreatic cancer patients in Ph 2 AMPLIFY-7P Trial September 23, 2025
IND application amended with updated OS data from Ph 2 Actuate-1801 Part 3B trial of elraglusib + GnP versus GnP alone in 1L metastatic pancreatic cancer September 23, 2025
First Patient Dosed in Ph 2 Study of AK130 + Ivonescimab for Advanced Pancreatic Cancer September 23, 2025
Final results from OPTIMIZE-1 trial of mitazalimab – mFOLFIRINOX combo in 1L metastatic pancreatic cancer patients announced September 23, 2025
New Data Supports Initiation of Ph 3 RASolute 303 Registrational Trial of Daraxonrasib in 1L Metastatic Pancreatic Ductal Adenocarcinoma September 16, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
Premarket approval (PMA) application submitted to FDA for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer August 26, 2025
ELI-002 Updated AMPLIFY-201 Ph 1 Follow-up Data published in Nature Medicine for MRD Positive, Adjuvant-Stage Patients August 19, 2025
Positive Recommendation by IDMC Announced: ELI-002 7P Ph 2 Study in Pancreatic Cancer to Continue Without Modifications to Final Analysis August 12, 2025
Ph 1b trial of elraglusib, retifanlimab, and mFOLFIRINOX combo as 1L therapy in advanced pancreatic adenocarcinoma initiated August 12, 2025
Mid-year report of Ampligen® (rintatolimod) & Imfinzi® combo in pancreatic cancer demonstrates no significant toxicity and superior PFS and OS August 12, 2025
Positive Mid-year Safety and Efficacy Data from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi Combo for the Treatment of Pancreatic Cancer Reported July 29, 2025
Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies announced July 15, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial of Certepetide + SoC chemo combo in Metastatic Pancreatic Cancer announced July 1, 2025
Revolution Medicines and Summit Therapeutics to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors July 1, 2025
First patient dosed in Ph 1/2 trial of TNG462 and daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer July 1, 2025
Positive OS Data for Atebimetinib (IMM-1-104) from Ph 2a Trial in 1L Pancreatic Cancer Patients Reported June 24, 2025
FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations June 24, 2025
